MP48-18 THE IMPACT OF LOCOREGIONAL TREATMENTS FOR METASTATIC CASTRATION RESISTANT PROSTATE CANCER ON DISEASE PROGRESSION: REAL LIFE EXPERIENCE FROM A MULTICENTER COHORT

Abstract

You have accessJournal of UrologyCME1 May 2022MP48-18 THE IMPACT OF LOCOREGIONAL TREATMENTS FOR METASTATIC CASTRATION RESISTANT PROSTATE CANCER ON DISEASE PROGRESSION: REAL LIFE EXPERIENCE FROM A MULTICENTER COHORT Mariaconsiglia Ferriero, Gabriele Tuderti, Umberto Anceschi, Alfredo Maria Bove, Aldo Brassetti, Leonardo Misuraca, Salvatore Guaglianone, Riccardo Mastroianni, Cosimo De Nunzio, Silvana Giacinti, Giorgia Tema, Luca Cindolo, Andrea Tubaro, Michele Gallucci, Luigi Schips, Fabio Calabrò, and Giuseppe Simone Mariaconsiglia FerrieroMariaconsiglia Ferriero More articles by this author , Gabriele TudertiGabriele Tuderti More articles by this author , Umberto AnceschiUmberto Anceschi More articles by this author , Alfredo Maria BoveAlfredo Maria Bove More articles by this author , Aldo BrassettiAldo Brassetti More articles by this author , Leonardo MisuracaLeonardo Misuraca More articles by this author , Salvatore GuaglianoneSalvatore Guaglianone More articles by this author , Riccardo MastroianniRiccardo Mastroianni More articles by this author , Cosimo De NunzioCosimo De Nunzio More articles by this author , Silvana GiacintiSilvana Giacinti More articles by this author , Giorgia TemaGiorgia Tema More articles by this author , Luca CindoloLuca Cindolo More articles by this author , Andrea TubaroAndrea Tubaro More articles by this author , Michele GallucciMichele Gallucci More articles by this author , Luigi SchipsLuigi Schips More articles by this author , Fabio CalabròFabio Calabrò More articles by this author , and Giuseppe SimoneGiuseppe Simone More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002619.18AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Available evidences on medical treatment of metastatic castration resistant prostate cancer (mCRPC), support the use of more than one therapy line to delay chemotherapy. In this study, we evaluate the role of locoregional treatments on disease progression of patients with mCRPC treated with Abiraterone Acetate (AA), and Enzalutamide (EZ) in a chemo-naïve setting from a longitudinal real life multicenter cohort. METHODS: We prospectively collected data on chemo-naïve mCRPC patients, who received either AA or EZ as first or second line treatment between Oct-2012 and Nov-2020 at 4 centers. Survival probabilities were computed at 12, 24, 48 and 60 months after treatment start. The impact of loco-regional treatments on progression free survival (PFS) were assessed with the Kaplan Meier method and the log-rank test was applied to assess statistical significance between groups. RESULTS: Overall, 117 chemo-naive mCRPC patients received a first line therapy. Clinical features of the cohort are reported in Table 1. Fifty-seven (48.7%) patients received AA and 60 (51.3%) received EZ. Eight (6.7%) patients underwent salvage chemotherapy after first line failure. Overall, 28 patients shifted to a second line therapy. Two-yr progression-free, cancer-specific and overall survival probabilities were 65.5%, 82.2% and 78.4% respectively. Since diagnosis of mCRPC, oligo progression occurred in 25 patients who received stereotactic radiation therapy (23/25, 92%) focused on metastasis (4 nodal sites and 19 bones) or salvage lymph node dissection (2/25, 8%). At Kaplan Meier analysis, high volume disease was significant predictors of lower PFS probabilities (log rank p=0.009). Loco-regional treatments did not impact significantly in PFS of the whole cohort and in patients with high volume disease (p=0.605 and p=0.752), while improved significantly PFS in patients with low volume disease (p=0.048) (Figure 1). CONCLUSIONS: Loco-regional therapies significantly impact on PFS in patients with low volume mCRPC disease and are useful treatments option to delay next line of therapy. Source of Funding: None © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e828 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Mariaconsiglia Ferriero More articles by this author Gabriele Tuderti More articles by this author Umberto Anceschi More articles by this author Alfredo Maria Bove More articles by this author Aldo Brassetti More articles by this author Leonardo Misuraca More articles by this author Salvatore Guaglianone More articles by this author Riccardo Mastroianni More articles by this author Cosimo De Nunzio More articles by this author Silvana Giacinti More articles by this author Giorgia Tema More articles by this author Luca Cindolo More articles by this author Andrea Tubaro More articles by this author Michele Gallucci More articles by this author Luigi Schips More articles by this author Fabio Calabrò More articles by this author Giuseppe Simone More articles by this author Expand All Advertisement PDF DownloadLoading ...